Pricing Log in Create free account

Orchestra BioMed Holdings, Inc. (OBIO) vs Relmada Therapeutics, Inc. (RLMD)

Orchestra BioMed Holdings, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Orchestra BioMed Holdings, Inc. and Relmada Therapeutics, Inc. are of similar size ($345.0M and $341.3M). Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −186.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Relmada Therapeutics, Inc. leads on 10 and Orchestra BioMed Holdings, Inc. on 3.

Valuation

Metric OBIO RLMD Biotechnology median
P/E n/m n/m 8.50
P/S 10.88 n/m 9.71
P/B 18.00 1.69 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.53 n/m 9.21
Earnings yield (15.60%) (29.03%) (33.15%)
Free cash flow yield (16.99%) (36.56%) (25.50%)

Profitability

Metric OBIO RLMD Biotechnology median
Gross margin 99.51% 0.00% 65.16%
Operating margin (181.36%) 0.00% 0.00%
Net margin (186.30%) 0.00% 0.00%
Free cash flow margin (184.83%) 0.00% 0.00%
Return on equity (607.32%) (55.66%) (56.36%)
Return on assets (75.16%) (51.57%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric OBIO RLMD Biotechnology median
Revenue growth (TTM) 986.14% — 6.02%
EPS growth (last fiscal year) 33.13% 45.28% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OBIO RLMD Biotechnology median
Debt to equity 1.80 0.00 0.00
Current ratio 8.26 29.52 4.72
Net debt to EBITDA 1.80 1.57 0.96

Dividend

Metric OBIO RLMD Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric OBIO RLMD Biotechnology median
Market cap 345.00m 341.34m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack